Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes
May 2013
Reps will promote Invokana (in-vo-KAHN-uh, canagliflozin), the first in a new class of oral drugs for type 2 diabetes.
You'll hear it referred to as an "SGLT2 inhibitor"...because it inhibits sodium-glucose co-transporter 2 in the kidneys. This allows more glucose to spill into the urine instead of being reabsorbed.
Reps will point out that Invokana reduces A1C by 1% when used alone...and it has a low risk of hypoglycemia.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote